Reasons for not receiving FLT3i treatment included HCT before maintenance therapy was routinely used in 2019 (n = 12), renal insufficiency (n = 1), FLT3-TKD only (n = 3), and early relapse (n = 2). This evidence concerns the gene FLT3 and Renal insufficiency.